【摘要】The invention relates to new application of TRIM66 protein, particularly application of TRIM66 protein in preparing a non-small cell lung cancer prognosis evaluation reagent or kit. The invention detects the expression rate of the TRIM66 in non-small cell lung cancer tissues is 70.5% which is higher than 51.4% of the para-carcinoma tissues. The invention detects the TRIM66 is related to the tumor size, depth of invasion, lymphatic metastasis and TNM staging of the non-small cell lung cancer, and the size of tumor, lymphatic metastasis, TNM staging and TRIM66 are independent factors for evaluating prognosis of the patients with non-small cell lung cancer. The invention also detects that the interference with the TRIM66 expression can inhibit the A549 cell proliferation.
